Time to add gemtuzumab ozogamicin to intensive chemotherapy for NPM1-mutated acute myeloid leukaemia?

Jad Othman¹, Richard Dillon²

Affiliations

¹ Department of Medical and Molecular Genetics, King's College, London SE1 9RT, UK; Department of Haematology, Royal North Shore Hospital, Sydney, Australia; Faculty of Medicine and Heath, University of Sydney, Australia.
² Department of Medical and Molecular Genetics, King's College, London SE1 9RT, UK; Department of Haematology, Guy's and St Thomas' Hospitals NHS Trust, London, UK. Electronic address: richard.dillon@kcl.ac.uk.

PMID: 37187197
DOI: 10.1016/S2352-3026(23)00092-3

Comment

Time to add gemtuzumab ozogamicin to intensive chemotherapy for NPM1-mutated acute myeloid leukaemia?

Jad Othman et al. Lancet Haematol. 2023 Jul.

. 2023 Jul;10(7):e478-e479.

doi: 10.1016/S2352-3026(23)00092-3. Epub 2023 May 12.

Authors

Jad Othman¹, Richard Dillon²

Affiliations

¹ Department of Medical and Molecular Genetics, King's College, London SE1 9RT, UK; Department of Haematology, Royal North Shore Hospital, Sydney, Australia; Faculty of Medicine and Heath, University of Sydney, Australia.
² Department of Medical and Molecular Genetics, King's College, London SE1 9RT, UK; Department of Haematology, Guy's and St Thomas' Hospitals NHS Trust, London, UK. Electronic address: richard.dillon@kcl.ac.uk.

PMID: 37187197
DOI: 10.1016/S2352-3026(23)00092-3

No abstract available

PubMed Disclaimer

Conflict of interest statement

RD declares research funding from Abbvie and Amgen; and speaker fees and consultancy from Abbvie, Astellas, Jazz, Servier, Shattuck, and Telix. JO declares no competing interests.

Comment on

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
Döhner H, Weber D, Krzykalla J, Fiedler W, Kühn MWM, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Fransecky L, Koller E, Wulf G, Schleicher J, Ringhoffer M, Greil R, Hertenstein B, Krauter J, Martens UM, Nachbaur D, Samra MA, Machherndl-Spandl S, Basara N, Leis C, Schrade A, Kapp-Schwoerer S, Cocciardi S, Bullinger L, Thol F, Heuser M, Paschka P, Gaidzik VI, Saadati M, Benner A, Schlenk RF, Döhner K, Ganser A; German–Austrian AML Study Group. Döhner H, et al. Lancet Haematol. 2023 Jul;10(7):e495-e509. doi: 10.1016/S2352-3026(23)00089-3. Epub 2023 May 12. Lancet Haematol. 2023. PMID: 37187198 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Grants and funding

29806/CRUK_/Cancer Research UK/United Kingdom

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Time to add gemtuzumab ozogamicin to intensive chemotherapy for NPM1-mutated acute myeloid leukaemia?

Affiliations

Time to add gemtuzumab ozogamicin to intensive chemotherapy for NPM1-mutated acute myeloid leukaemia?

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical